CHARLES F. LETTOW, District Judge.
Pending before the court are four motions in limine filed in anticipation of the scheduled trial of this patent case involving the military's so-called "green bullet." Two motions were filed by the government and the other two were filed by plaintiff Liberty Ammunition, Inc. ("Liberty").
The NDA signed on behalf of the government by Mr. Campion ("Campion NDA") is dated June 23, 2005, see Liberty Ammunition, Inc. v. United States, 101 Fed. Cl. 581, 584 (2011), at a time when Mr. Campion, a government contractor, was serving as the project manager for the Program Executive Office for Special Projects at the United States Special Operations Command ("SOCOM"), Def.'s Mot. in Limine to Exclude the Non-Disclosure Agreement Signed by Thomas Campion and Testimony Relating to the Same ("Def.'s Mot. to Exclude Campion NDA") at 2, ECF No. 52. During that period, he was having discussions with Mr. PJ Marx, the inventor, regarding Mr. Marx's bullet design. Id.; see also Pl.'s Resp. to Def.'s Mot. to Exclude Campion NDA at 2-3, ECF No. 62.
Liberty agrees with the concept that government contractors generally are not authorized to execute contracts on behalf of the government, but it argues that exceptions apply in this case. Pl.'s Resp. to Def.'s Mot. to Exclude Campion NDA at 6-11. Liberty contends that Mr. Campion, by nature of his position, possessed express actual authority to contractually bind the government. Id. at 6.
The government also contends that even if it is bound by the Campion NDA, the Anti-Assignment Act, 41 U.S.C. § 6305 (formerly codified as 41 U.S.C. § 15), bars Liberty's breach of contract claim. See Def.'s Mot. to Exclude Campion NDA at 5-8.
The government previously presented this argument to the court in connection with a motion to dismiss. As explained in a prior opinion resolving that motion, any decision regarding whether the Campion NDA is subject to the Anti-Assignment Act turns on disputed issues of fact that should be determined through testimony and evidence at trial. Liberty Ammunition, 101 Fed. Cl. at 587.
A NDA signed by Mr. Marsh on behalf of the government ("Marsh NDA") is also at issue.
In addition, the government reiterates an argument based upon the Anti-Assignment Act that is identical to a contention it makes relating to the Campion NDA. Def.'s Mot. to Exclude Marsh NDA at 5. Here also, the court concludes that the questions respecting applicability of the Anti-Assignment Act and the exceptions to that Act can only be resolved through trial.
Liberty requests exclusion of all testimony and evidence related to the Army's purported independent development of the allegedly infringing products, the M855A1 EPR and M80A1 EPR bullets (collectively "the A1 technology"). See Pl.'s Mot. in Limine to Preclude Any and All Trial Evidence Offered by Def. Regarding Supposed "Independent Development" of the M855A1 EPR & M80A1 EPR Rounds ("Pl.'s Mot. to Exclude Evid. of Indep. Dev."), ECF No. 55. As part of its case in chief, Liberty seeks to prove that the government developed the M855A1 EPR and M80A1 EPR rounds through misappropriated proprietary information, in violation of its NDAs. Id. at 3-4. Liberty puts forward two grounds for its motion to exclude evidence of independent development. First, Liberty cites the absence of any research notebooks, required by Army Reg. 27-60, which might serve as corroboration to oral testimony of such development. Id. at 7-11 & Ex. H (Army Reg. 27-60), ¶ 2-3. Second, Liberty argues that Fed. R. Evid. 1002, which sets out requirements for original documentation, precludes admission of oral testimony in place of such documentation. Id. at 12-13.
Liberty's reliance on Fed. R. Evid. 1002 is unavailing. The rule is intended to be applied when the contents of a writing are at issue and to ensure that the writing itself, or a suitable duplicate, is produced. See R & R Assocs. v. Visual Scene, Inc., 726 F.2d 36, 38 (1st Cir. 1984) ("No evidentiary rule, however, prohibits a witness from testifying to a fact simply because the fact can be supported by written documentation."). While laboratory notebooks would be relevant evidence of independent development, the apparent non-existence of such notebooks does not mean that oral testimony on that topic cannot be presented. A witness can testify about any relevant and non-prejudicial subject of which he or she has personal knowledge, see Fed. R. Evid. 104, 403, and 602, assuming that the other Federal Rules of Evidence are satisfied.
Notably, however, the court may not look favorably on testimony of independent development that lacks corroboration by evidence that would normally be available in a patent case. See Medichem, S.A., v. Rolabo, S.L., 437 F.3d 1157, 1169-73 (Fed. Cir. 2006) (finding that oral testimony was not sufficient to corroborate an inventor's claims of reduction to practice of an invention). That said, the weight to be accorded a witness's testimony or the contents of any corroborating documents must be resolved during trial.
Liberty also seeks to exclude the February 2014 ex parte tests of prior art in the form of M855 and M855 LFS projectiles conducted at the direction of one of the government's experts after discovery closed and without notice to Liberty. See Pl.'s Mot. in Limine to Exclude Feb. 2014 Ex Parte M855 and M855 LFS Tests by Def. ("Pl.'s Mot. to Exclude Tests") at 6, ECF No. 54 (citing In re Newman, 782 F.2d 971, 974 (Fed. Cir. 1986) (finding a lack of "fundamental fairness" in ex parte tests that deviated too greatly from safeguards found in Fed. R. Civ. P. 34)). These tests were performed as part of the government's litigation strategy to generate information to be used by its expert witness. See Def.'s Opp'n to Pl.'s Mot. to Exclude Tests at 4-6, ECF No. 60. The government apparently seeks to use the results of these tests, along with expert testimony, to support its argument that the patent at issue is invalid because it was anticipated by the M855 and M855 LFS ammunition, which were both in the prior art. Id.
Liberty argues that the tests should be excluded because of the lack of objectivity of the tester and the self-serving nature of the circumstances. Pl.'s Mot. to Exclude Tests at 7 ("Ex parte tests are viewed with suspicion `because acts that are not observed or corroborated by an opposing party may be entirely self-serving.'" (quoting Amgen, Inc. v. Chugai Pharm. Co., No. 87-2617-Y, 1989 WL 169006, at *64 (D. Mass. Dec. 11, 1989), rev'd on other grounds, 927 F.2d 1200 (Fed. Cir. 1991))). Liberty additionally argues that the ex parte tests were prejudicial because the government waited to release the results until after the relevant expert reports were exchanged. Pl.'s Mot. to Exclude Tests at 7. Alternatively, Liberty maintains that even if the tests were to be admitted, any expert testimony relying on them should receive little or negligible weight. Id. at 6 (citing Ralston Purina Co. v. Far-Mar-Co, Inc., 586 F.Supp. 1176, 1214 (D. Kan. 1984), rev'd on other grounds, 772 F.2d 1570 (Fed. Cir. 1985)).
The government responds by contending that the testing gives rise to an issue of fact that should be determined at trial. Def.'s Opp'n to Pl.'s Mot. to Exclude Tests at 7-8. It argues that the tests results are potentially admissible for two reasons. First, ex parte tests that follow proper procedural safeguards can be given evidentiary consideration. Id. at 8 (citing Congoleum Indus., Inc. v. Armstrong Cork Co., 319 F.Supp. 714, 716 (E.D. Pa. 1970)).
For the reasons stated, both of the government's motions in limine and both of Liberty's motions in limine are DENIED.
It is so ORDERED.
48 C.F.R. § 2.101 ("Definitions — `Acquisition'"). The government fails to explain why FAR provisions should apply to the NDA.